About Korro Bio, Inc.
https://www.korrobio.comKorro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
CEO
Ram Aiyar MBA,
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-11-06 | Reverse | 1:50 |
ETFs Holding This Stock
Summary
Showing Top 3 of 55
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Raymond James
Strong Buy
Oppenheimer
Outperform
William Blair
Market Perform
RBC Capital
Sector Perform
Chardan Capital
Neutral
HC Wainwright & Co.
Neutral
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC
Shares:1.14M
Value:$10.23M
NEA MANAGEMENT COMPANY, LLC
Shares:1.09M
Value:$9.82M
DRIEHAUS CAPITAL MANAGEMENT LLC
Shares:671.98K
Value:$6.05M
Summary
Showing Top 3 of 96
About Korro Bio, Inc.
https://www.korrobio.comKorro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.09M ▼ | $20.33M ▼ | $-18.06M ▲ | -1.66K% ▲ | $-1.92 ▲ | $-16.88M ▲ |
| Q2-2025 | $1.46M ▼ | $28.66M ▲ | $-25.77M ▼ | -1.77K% ▼ | $-2.74 ▼ | $-25.98M ▼ |
| Q1-2025 | $2.55M ▲ | $27.57M ▲ | $-23.39M ▼ | -917.14% ▲ | $-2.49 ▼ | $-23.8M ▼ |
| Q4-2024 | $2.27M ▲ | $25.31M ▲ | $-21.2M ▼ | -933.47% ▼ | $-2.26 | $-21.79M ▲ |
| Q3-2024 | $0 | $23.29M | $-21M | 0% | $-2.26 | $-22.43M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $93.48M ▼ | $161.55M ▼ | $62.52M ▼ | $99.03M ▼ |
| Q2-2025 | $96.36M ▼ | $180.43M ▼ | $65.32M ▲ | $115.1M ▼ |
| Q1-2025 | $114.95M ▼ | $202.21M ▼ | $63.25M ▼ | $138.96M ▼ |
| Q4-2024 | $126.09M ▼ | $226.24M ▼ | $65.83M ▲ | $160.41M ▼ |
| Q3-2024 | $137M | $243.54M | $63.91M | $179.63M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-18.06M ▲ | $-17.18M ▲ | $7.6M ▲ | $128K ▲ | $-9.46M ▲ | $-17.35M ▲ |
| Q2-2025 | $-25.77M ▼ | $-19.23M ▲ | $-11.3M ▼ | $5K ▼ | $-29.53M ▼ | $-19.37M ▲ |
| Q1-2025 | $-23.39M ▼ | $-24.45M ▼ | $32.78M ▲ | $172K ▼ | $8.5M ▲ | $-24.57M ▼ |
| Q4-2024 | $-21.2M ▼ | $-7.5M ▲ | $-2.77M ▲ | $932K ▲ | $-9.33M ▲ | $-8.95M ▲ |
| Q3-2024 | $-21M | $-16.09M | $-12.58M | $728K | $-27.95M | $-20.97M |
CEO
Ram Aiyar MBA,
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-11-06 | Reverse | 1:50 |
ETFs Holding This Stock
Summary
Showing Top 3 of 55
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Raymond James
Strong Buy
Oppenheimer
Outperform
William Blair
Market Perform
RBC Capital
Sector Perform
Chardan Capital
Neutral
HC Wainwright & Co.
Neutral
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC
Shares:1.14M
Value:$10.23M
NEA MANAGEMENT COMPANY, LLC
Shares:1.09M
Value:$9.82M
DRIEHAUS CAPITAL MANAGEMENT LLC
Shares:671.98K
Value:$6.05M
Summary
Showing Top 3 of 96